People_
Dr Cristina Mapagu
Clinical Research Fellow
Westmead Clinical School
Westmead Clinical School
| Project title | Research student |
|---|---|
| Mechanisms underlying homologous recombination DNA repair deficiency in ovarian cancer and association with treatment response | Nikilyn NEVINS |
Publications
Expand all
Journals
- Pitiyarachchi, O., Lee, Y., Sim, H., Srirangan, S., Mapagu, C., Kirk, J., Harnett, P., Balleine, R., Bowtell, D., Samimi, G., Brand, A., Marsh, D., Beale, P., Anderson, L., Bouantoun, N., Provan, P., deFazio, A., et al (2023). Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. Translational Oncology, 31. [More Information]
- Siu, D., Ali, A., Tjokrowidjaja, A., De Silva, M., Lee, J., Clingan, P., Aghmesheh, M., Brungs, D., Mapagu, C., Goldstein, D., Sjoquist, K., Pavlakis, N., Clarke, S., Diakos, C., et al (2022). Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. Asia-Pacific Journal of Clinical Oncology, 18(6), 660-668. [More Information]
- Kok, P., Beale, P., O'Connell, R., Grant, P., Bonaventura, T., Scurry, J., Antill, Y., Goh, J., Sjoquist, K., deFazio, A., Mapagu, C., et al (2019). PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. Journal of Gynecologic Oncology, 30(5), 1-14. [More Information]
show 3 more
Expand all
2023
- Pitiyarachchi, O., Lee, Y., Sim, H., Srirangan, S., Mapagu, C., Kirk, J., Harnett, P., Balleine, R., Bowtell, D., Samimi, G., Brand, A., Marsh, D., Beale, P., Anderson, L., Bouantoun, N., Provan, P., deFazio, A., et al (2023). Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. Translational Oncology, 31. [More Information]
2022
- Siu, D., Ali, A., Tjokrowidjaja, A., De Silva, M., Lee, J., Clingan, P., Aghmesheh, M., Brungs, D., Mapagu, C., Goldstein, D., Sjoquist, K., Pavlakis, N., Clarke, S., Diakos, C., et al (2022). Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. Asia-Pacific Journal of Clinical Oncology, 18(6), 660-668. [More Information]
2019
- Kok, P., Beale, P., O'Connell, R., Grant, P., Bonaventura, T., Scurry, J., Antill, Y., Goh, J., Sjoquist, K., deFazio, A., Mapagu, C., et al (2019). PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. Journal of Gynecologic Oncology, 30(5), 1-14. [More Information]
2018
- Lindemann, K., Gao, B., Mapagu, C., Fereday, S., Emmanuel, C., Alsop, K., Traficante, N., Harnett, P., Bowtell, D., deFazio, A. (2018). Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecologic Oncology, 150(2), 239-246. [More Information]
2017
- Bonaventura, A., O'Connell, R., Mapagu, C., Beale, P., McNally, O., Mileshkin, L., Grant, P., Hadley, A., Goh, J., Sjoquist, K., Martyn, J., deFazio, A., et al (2017). Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer. International Journal of Gynecological Cancer, 27(5), 900-906. [More Information]
2003
- Mapagu, C., Lam, A., Fitzgerald, D., Martin, H. (2003). Intermittent intussusception. Journal of Paediatrics and Child Health, 11, 147-148. [More Information]